Experimental and Computational Approaches for SARS-CoV-2 Theranostics

Ijaz      Gul; Mohammad   Amjad   Kamal

doi:10.2174/138161282846221227231152

« Previous

[1]
World Health Organization.. COVID-19 Weekly Epidemiological Update 2022.

[2]
Kuzmina A, Khalaila Y, Voloshin O, et al. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe  2021; 29(4): 522-8.e2.

[3]

https://www.imf.org/en/Topics/imf-and-covid19/Policy-Responses-to-COVID-19.

[4]
Chavda VP, Patel AB, Vora LK, et al. Nitric oxide and its derivatives containing nasal spray and inhalation therapy for the treatment of COVID-19. Curr Pharm Des  2022; 28: 3658-70.

[5]
Yadav D, Song M. Therapeutic applications of fucoidans and their potential to act against COVID-19. Curr Pharm Des  2022; 28: 3671-6.

[6]
Ansari MA, Alomary MN, Jamal QMS, et al. State-of-the-art Tools to Elucidate the therapeutic potential of TAT-peptide (TP) conjugated repurposing drug against SARS-CoV-2 spike glycoproteins. Curr Pharm Des  2022; 28: 3706-19.

[7]
Malla RR, Kamal MA. Tetraspanin-enriched microdomain containing CD151, CD9, and TSPAN 8 – Potential mediators of entry and exit mechanisms in respiratory viruses including SARS-CoV-2. Curr Pharm Des  2022; 28: 3649-57.

[8]
Pauly I, Singh AK, Kumar A, et al. Current insights and molecular docking studies of the drugs under clinical trial as RdRp inhibitors in COVID-19 treatment. Curr Pharm Des  2022; 28: 3677-705.

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/138161282846221227231152	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

Current Pharmaceutical Design

Experimental and Computational Approaches for SARS-CoV-2 Theranostics

Related Journals

Related Books